Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
QLT Inc.
This proof-of-concept study is a randomized, parallel design of two different oral doses of QLT091001 compared to placebo to evaluate treatment effects in patients with impaired dark adaptation.
Approximately 40 subjects will be enrolled in this study at approximately 7 centers in the US.
Age
60–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Male or female subjects ≥60 yrs with early age-related macular degeneration (AMD) based on LLLC BCVA criterion or evidence of impaired dark adaptation
Subjects with high luminance high contrast best-corrected visual acuity (HLHC BCVA) of 40 letters (20/40 Snellen) or better in the study eye
Capable and willing to provide consent
You may not be if
Women of child bearing potential
Subjects with late AMD or any other optic neuropathy in the study eye
Subjects with posterior subcapsular cataract or multifocal intra-ocular lens (IOL) in the study eye
Subjects who are actively participating in an experimental therapy study or who have received experimental therapy within 60 days of Day 0 or who have taken any prescription/investigational oral retinoid medication within 6 months of Day 0
Subjects taking age-related eye disease study (AREDS) supplements containing beta-carotene
Clareo Health | Evaluation of the Effects of Oral QLT091001 in Adults With Impaired Dark Adaptation
